1.Anon (2017) UNAIDS. Joint United Nations Program on HIV/AIDS and World Health Organization. UNAIDS report on the Global AIDS Epidemic. Available at http://www.unaids.org/ (Accessed 31 January 2018).
3.Kline, ER and Sutliff, RL (2008) The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. Journal of Investigative Medicine 56, 752–769.
4.Fiala, M et al. (2004) HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovascular Toxicology 4, 97–107.
5.Boccara, F et al. (2013) HIV and coronary heart disease: time for a better understanding. Journal of the American College of Cardiology 61, 511–523.
6.Butt, AA et al. (2011) Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Archives of Internal Medicine 171, 737–743.
7.Farahani, M et al. (2017) Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. International Journal of STD & AIDS 28, 636–650.
8.O'Halloran, JA et al. (2015) The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Medicine 16, 608–619.
9.Capeau, J (2007) From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging. Current Opinion in HIV and AIDS 2, 247–252.
10.Boccara, F et al. (2010) HIV protease inhibitors activate the adipocyte renin angiotensin system. Antiviral Therapy 15, 363–375.
11.Chen, YM and Kuo, SH (2007) HIV-1 in Taiwan. The Lancet 369: 623–625.
13.Chao, TF et al. (2017) Risk and prediction of sudden cardiac death and ventricular arrhythmias for patients with atrial fibrillation – a nationwide cohort study. Scientific Reports 7, 46445.
14.Liang, FW et al. (2017) Regional and hospital variations in the extent of decline in the proportion of percutaneous coronary interventions performed for nonacute indications – a nationwide population-based study. BMC Cardiovascular Disorders 17, 149.
15.Grunfeld, C et al. (2009) Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (London, England) 23, 1841–1849.
16.Kuller, LH et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine 5, e203.
17.Neuhaus, J et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. The Journal of Infectious Disease 201, 1788–1795.
18.Sodora, DL and Silvestri, G (2008) Immune activation and AIDS pathogenesis. AIDS (London, England) 22, 439–446.
19.Lang, S et al. (2012) HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clinical Infectious Diseases 55, 600–607.
20.Lo, J et al. (2010) Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS (London, England) 24, 243–253.
21.Hunt, PW et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. The Journal of Infectious Diseases 197, 126–133.
22.Al-Kindi, SG et al. (2016) Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. International Journal of Cardiology 218, 43–46.
23.Freiberg, MS et al. (2017) Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy Era: results from the veterans aging cohort study. JAMA Cardiology 2, 536–546.
24.Twu, C et al. (2002) Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proceedings of the National Academy of Sciences of the USA 99, 14386–14391.
25.Magnani, JW and Dec, GW (2006) Myocarditis: current trends in diagnosis and treatment. Circulation 113, 876–890.
26.Monsuez, JJ et al. (2007) Cytokines in HIV-associated cardiomyopathy. International Journal of Cardiology 120, 150–157.
27.Durand, M et al. (2013) Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study. Journal of Stroke and Cerebrovascular Diseases 22, e34–e41.
28.Rasmussen, LD et al. (2011) Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS (London, England) 25, 1637–1646.
29.Goldstein, DA, Timpone, J and Cupps, TR (2010) HIV-associated intracranial aneurysmal vasculopathy in adults. The Journal of Rheumatology 37, 226–233.
30.Chetty, R, Batitang, S and Nair, R (2000) Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Human Pathology 31, 374–379.
31.Campos, P, Ortiz, A and Soto, K (2016) HIV and kidney diseases: 35 years of history and consequences. Clinical Kidney Journal 9, 772–781.
32.Cohen, SD, Kopp, JB and Kimmel, PL (2017) Kidney diseases associated with human immunodeficiency virus infection. The New England Journal of Medicine 377, 2363–2374.
33.Estrella, MM and Fine, DM (2010) Screening for chronic kidney disease in HIV-infected patients. Advances in Chronic Kidney Disease 17, 26–35.